Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frailty-adjusted IRD induction and R vs R+I maintenance in transplant-ineligible newly diagnosed multiple myeloma
2018-003590-10Phase 3Unknown
- Sponsor
- University of Leeds
- Start
- Sep 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ixazomib, lenalidomide and dexamethasone in multiple myeloma (MM) (4 arms), sponsored by University of Leeds. Primary endpoint: Early treatment cessation (Randomisation 1). Status: unknown.
02
Drugs
ixazomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2018-003590-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003590-10.